A clinical trial led by clinicians at Georgetown Lombardi Comprehensive Cancer Center showed a remarkable 20% advantage in the two-year OS rate for people with advanced melanoma who first received immunotherapy (72% survival rate) versus those who initially got targeted therapies (52% survival rate). Progression-free survival, where the cancer is stable or improving, was also trending in favor of those who started on immunotherapy.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe